Background: Previous analysis clustered 1,238 individuals from the
general population Genetics of Lipid Lowering Drugs Network (GOLDN) study by the size
of their fasting very low-density, low-density and high-density lipoproteins (VLDL,
LDL, HDL) using latent class analysis. From two of the eight identified groups (N =
251), ~75% of indiv... read moreiduals met Adult Treatment Panel III criteria for the metabolic
syndrome (MetS). Both showed small LDL diameter (mean = 19.9 nm); however, group 1 (N
= 200) had medium VLDL diameter (mean = 53.1 nm) while group 2 had very large VLDL
diameter (mean = 65.74 nm). Group 2 additionally showed significantly more insulin
resistance (IR), and accompanying higher waist circumference and fasting glucose and
triglycerides (all P < .01). Since lipoprotein lipase hydrolyzes triglyceride in
the VLDL-LDL cascade, we examined whether these two patterns of lipoprotein diameter
were associated with differences across two lipoprotein lipase (LPL) gene variants:
D9N (rs1801177) and S447X (rs328).
Wood, Alexis, Stephen Glasser, W. Timothy Garvey, Edmond K.
Kabagambe, Ingrid B. Borecki, Hemant K. Tiwari, Michael Y. Tsai, Paul N. Hopkins,
Jose M. Ordovas, and Donna K. Arnett. "Lipoprotein Lipase S447X variant associated
with VLDL, LDL and HDL diameter clustering in the MetS." Lipids in Health and Disease
10, no. 1 (12, 2011): 1-4.